Vaxcyte says Phase 3 OPUS-1 trial of VAX-31 meets primary endpoints in adults versus Prevnar 20, Capvaxive
Bitget2026/10/05 10:05Vaxcyte reported positive topline results from OPUS-1, a pivotal adult Phase 3 trial of its VAX-31 pneumococcal vaccine. The study met its primary goals across age groups, supporting the program’s case for regulatory filing in the US. Results indicated immune responses broadly comparable to leading adult pneumococcal vaccines, with added coverage for strains not included in them. Safety and tolerability were broadly similar to existing comparator vaccines in the trial. Additional Phase 3 readouts are expected in the first half of 2027, ahead of a planned BLA submission in the first half of 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050600PRIMZONEFULLFEED9839330) on October 05, 2026, and is solely responsible for the information contained therein.
- Vaxcyte reported positive topline results from OPUS-1, a pivotal adult Phase 3 trial of its VAX-31 pneumococcal vaccine.
- The study met its primary goals across age groups, supporting the program’s case for regulatory filing in the US.
- Results indicated immune responses broadly comparable to leading adult pneumococcal vaccines, with added coverage for strains not included in them.
- Safety and tolerability were broadly similar to existing comparator vaccines in the trial.
- Additional Phase 3 readouts are expected in the first half of 2027, ahead of a planned BLA submission in the first half of 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."
Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.
Chun purchased 7,186 ETH worth $11.74 million


Philadelphia Fed President Paulson: Consecutive rate hikes not ruled out, but emphasizes “measured pace”
Philadelphia Fed President Paulson stated that he is willing to consider consecutive rate hikes to curb inflation, but emphasized that this should be done at a "prudent" pace. He indicated that interest rates need to continue rising and remains "open" to consecutive hikes, but refused to commit to a specific pace. Currently, the U.S. economy is performing well and the labor market remains strong, providing room for tighter policy, but tackling inflation remains the top priority.
